NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Forecast, Price & News $1.50 -0.08 (-5.06%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$1.48▼$1.6150-Day Range$1.50▼$2.2452-Week Range$0.72▼$2.69Volume278,257 shsAverage Volume410,754 shsMarket Capitalization$100.10 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aquestive Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside300.0% Upside$6.00 Price TargetShort InterestHealthy2.73% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.25) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector693rd out of 962 stocksPharmaceutical Preparations Industry312th out of 449 stocks 3.5 Analyst's Opinion Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Aquestive Therapeutics has a forecasted upside of 300.0% from its current price of $1.50.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.73% of the outstanding shares of Aquestive Therapeutics have been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 7.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AQST. Previous Next 2.4 News and Social Media Coverage News SentimentAquestive Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Aquestive Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows9 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.39% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.91% of the stock of Aquestive Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.25) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Aquestive Therapeutics (NASDAQ:AQST) StockAquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.Read More AQST Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AQST Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comWedbush Reiterates "Outperform" Rating for Aquestive Therapeutics (NASDAQ:AQST)September 24, 2023 | americanbankingnews.comAquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC WainwrightSeptember 26, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 23, 2023 | americanbankingnews.comAquestive Therapeutics' (AQST) "Market Outperform" Rating Reiterated at JMP SecuritiesSeptember 22, 2023 | msn.comARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In BothSeptember 21, 2023 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)September 21, 2023 | americanbankingnews.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Decline in Short InterestSeptember 20, 2023 | finance.yahoo.comAquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual FilmSeptember 26, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 15, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Gains As Market Dips: What You Should KnowSeptember 13, 2023 | finance.yahoo.comAquestive Therapeutics (AQST) Flat As Market Gains: What You Should KnowSeptember 11, 2023 | finance.yahoo.comAquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) DateAugust 11, 2023 | finance.yahoo.comAquestive Therapeutics, Inc.'s (NASDAQ:AQST) 11% loss last week hit both individual investors who own 60% as well as institutionsAugust 10, 2023 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Aquestive Therapeutics (AQST)August 8, 2023 | markets.businessinsider.comAquestive Therapeutics (AQST) Receives a Buy from JMP SecuritiesAugust 7, 2023 | finance.yahoo.comAquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 7, 2023 | finance.yahoo.comAquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 2, 2023 | finance.yahoo.comAquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare ConferenceJuly 31, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Aquestive Therapeutics (AQST)July 27, 2023 | finance.yahoo.comAquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual FilmJuly 26, 2023 | seekingalpha.comAquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis ProblemJuly 25, 2023 | finance.yahoo.comAquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ETJuly 25, 2023 | finance.yahoo.comAquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy ConferenceJuly 21, 2023 | msn.comAquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should KnowJuly 18, 2023 | msn.comAquestive Therapeutics (AQST) Outpaces Stock Market Gains: What You Should KnowJuly 14, 2023 | finance.yahoo.comAre Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?See More Headlines Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Company Calendar Last Earnings8/07/2023Today9/25/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AQST CUSIPN/A CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+300.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,410,000.00 Net Margins-48.61% Pretax Margin-48.00% Return on EquityN/A Return on Assets-39.81% Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio0.88 Sales & Book Value Annual Sales$47.68 million Price / Sales2.10 Cash FlowN/A Price / Cash FlowN/A Book Value($2.19) per share Price / Book-0.68Miscellaneous Outstanding Shares66,730,000Free Float61,129,000Market Cap$100.10 million OptionableNot Optionable Beta2.63 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Daniel Barber (Age 47)CEO, Pres & Director Comp: $925.35kMr. Alexander Mark Schobel (Age 64)Chief Innovation & Technology Officer Comp: $672.69kMs. Lori J. Braender BSBA (Age 67)Esq., J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. Comp: $678.76kMr. A. Ernest Toth Jr. (Age 64)Chief Financial Officer Ms. Cassie Jung (Age 44)Sr. VP of Operations Mr. Peter E. Boyd (Age 57)Sr. VP of IT, HR & Communications Mr. Kenneth W. Marshall (Age 64)Chief Commercial Officer Dr. Gary H. Slatko M.D. (Age 66)MBA, Chief Medical Officer Dr. Stephen Wargacki (Age 45)Sr. VP of R&D Dr. Carl N. Kraus M.D. (Age 53)Chief Medical Officer More ExecutivesKey CompetitorsEvelo BiosciencesNASDAQ:EVLOAnnovis BioNYSE:ANVSChimerixNASDAQ:CMRXAbeona TherapeuticsNASDAQ:ABEOBriaCell TherapeuticsNASDAQ:BCTXView All CompetitorsInstitutional OwnershipWalleye Capital LLCBought 403,898 shares on 8/15/2023Ownership: 0.654%XTX Topco LtdBought 138,145 shares on 8/15/2023Ownership: 0.224%Beacon Pointe Advisors LLCBought 60,000 shares on 8/15/2023Ownership: 0.097%Goldman Sachs Group Inc.Bought 57,149 shares on 8/15/2023Ownership: 0.093%Citadel Advisors LLCBought 500 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions AQST Stock - Frequently Asked Questions Should I buy or sell Aquestive Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares. View AQST analyst ratings or view top-rated stocks. What is Aquestive Therapeutics' stock price forecast for 2023? 4 Wall Street research analysts have issued 12 month price targets for Aquestive Therapeutics' shares. Their AQST share price forecasts range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 300.0% from the stock's current price. View analysts price targets for AQST or view top-rated stocks among Wall Street analysts. How have AQST shares performed in 2023? Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of the year. Since then, AQST stock has increased by 66.3% and is now trading at $1.50. View the best growth stocks for 2023 here. Are investors shorting Aquestive Therapeutics? Aquestive Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,820,000 shares, a drop of 7.1% from the August 15th total of 1,960,000 shares. Based on an average daily trading volume, of 374,400 shares, the days-to-cover ratio is presently 4.9 days. View Aquestive Therapeutics' Short Interest. When is Aquestive Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our AQST earnings forecast. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm earned $13.24 million during the quarter, compared to analyst estimates of $10.76 million. What guidance has Aquestive Therapeutics issued on next quarter's earnings? Aquestive Therapeutics issued an update on its FY 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $44.00 million-$48.00 million, compared to the consensus revenue estimate of $43.37 million. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB). When did Aquestive Therapeutics IPO? (AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. What is Aquestive Therapeutics' stock symbol? Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST." Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.99%), Geode Capital Management LLC (0.67%), BlackRock Inc. (0.66%), Walleye Capital LLC (0.65%), Marshall Wace LLP (0.44%) and Acadian Asset Management LLC (0.29%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aquestive Therapeutics' stock price today? One share of AQST stock can currently be purchased for approximately $1.50. How much money does Aquestive Therapeutics make? Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $100.10 million and generates $47.68 million in revenue each year. The company earns $-54,410,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis. How many employees does Aquestive Therapeutics have? The company employs 130 workers across the globe. How can I contact Aquestive Therapeutics? Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com. This page (NASDAQ:AQST) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.